Literature DB >> 10787010

Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis.

M Arora1, R Arora, S C Tiwari, N Das, L M Srivastava.   

Abstract

This study assessed the expression of complement receptor 1 (CR1), decay accelerating factor (DAF) and membrane inhibitor of reactive lysis (CD59) on the erythrocytes and glomerulus of diffuse proliferative glomerulonephritis (DPGN) of systemic lupus erythematosus (SLE) patients using flow cytometry and immunofluorescence techniques to elucidate their role in the pathogenesis of DPGN. Expression of CR1 on the erythrocytes and glomerulus of DPGN patients was reduced compared with expression in normal subjects. However, expression of DAF and CD59 was increased on both erythrocytes and glomerulus of DPGN patients, suggesting the generation of a protective response against complement-mediated injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10787010     DOI: 10.1191/096120300678828154

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

2.  Role of decay-accelerating factor in regulating survival of human cervical cancer cells.

Authors:  Ling-Juan Gao; Lan Ding; Shu-Yu Guo; You-Qun Cai; Ya-Juan Su; Hui Gong; Yun Liu; Chen Chen; Ping-Qing Gu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-10       Impact factor: 4.553

3.  Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells.

Authors:  Ling-Juan Gao; Shu-Yu Guo; You-Qun Cai; Ping-Qing Gu; Ya-Juan Su; Hui Gong; Yun Liu; Chen Chen
Journal:  BMC Cancer       Date:  2009-10-30       Impact factor: 4.430

4.  Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Authors:  Vasil V Vasilev; Remi Noe; Marie-Agnes Dragon-Durey; Sophie Chauvet; Valentin J Lazarov; Boriana P Deliyska; Veronique Fremeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

5.  Diminished expression of complement regulatory proteins on peripheral blood cells from systemic lupus erythematosus patients.

Authors:  Ana Paula Alegretti; Laiana Schneider; Amanda Kirchner Piccoli; Odirlei Andre Monticielo; Priscila Schmidt Lora; João Carlos Tavares Brenol; Ricardo Machado Xavier
Journal:  Clin Dev Immunol       Date:  2012-06-12

6.  The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.

Authors:  John V Asimakopoulos; Evangelos Terpos; Loula Papageorgiou; Olga Kampouropoulou; Dimitris Christoulas; Anastasios Giakoumis; Michael Samarkos; George Vaiopoulos; Konstantinos Konstantopoulos; Maria K Angelopoulou; Theodoros P Vassilakopoulos; John Meletis
Journal:  Med Sci Monit       Date:  2014-01-27

7.  Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease.

Authors:  Dalia Mahmoud Eldewi; Alshaymaa M Alhabibi; Hanaa Mohammed Eid El Sayed; Sammar Ahmed Kasim Mahmoud; Sanaa Mohammed El Sadek; Rasha Mahmoud Gouda; Mohammed Abd El Malik Hassan; Amal H Ibrahim; Naglaa F Abd El Haliem
Journal:  Int J Gen Med       Date:  2019-09-16

8.  The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?

Authors:  Anna Kubiak-Wlekły; Agnieszka Perkowska-Ptasińska; Paweł Olejniczak; Aleksandra Rochowiak; Elżbieta Kaczmarek; Magdalena Durlik; Stanisław Czekalski; Zofia I Niemir
Journal:  Int J Biomed Sci       Date:  2009-03

Review 9.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.